Synthesis and anti-HBV activities evaluation of new ethyl 8-imidazolylmethyl-7-hydroxyquinoline-3-carboxylate derivatives in vitro

Archiv der Pharmazie

Volumn 341, Issue 7, 2008, Pages 446-452

  Liu, Yajing ^a   Zhao, Yanfang ^a   Zhai, Xin ^a   Liu, Xiuping ^b   Sun, Lixue ^a   Ren, Yanxia ^a   Gong, Ping ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b HEBEI UNIVERSITY   (China)

Author keywords

7 Hydroxyquinoline 3 carboxylates; Anti HBV activities; Synthesis

Indexed keywords

ETHYL 2 [(4 CHLOROBENZYLSULFINYL)METHYL] 7 HYDROXY 6 METHOXY 8 [(2 METHYL 1H IMIDAZOL 1 YL)METHYL]QUINOLINE 3 CARBOXYLATE; ETHYL 2 [(4 CHLOROBENZYLSULFINYL)METHYL] 7 HYDROXY 6 METHOXY 8 [(2 METHYL 1H IMIDAZOL 1YL)METHYL]QUINOLINE 3 CARBOXYLATE; ETHYL 2 [(4 CHLOROBENZYLSULFONYL)METHYL] 7 HYDROXY 6 METHOXY 8 [(2 METHYL 1H IMIDAZOL 1 YL)QUINOLINE 3 CARBOXYLATE; ETHYL 2 [(4 CHLOROBENZYLTHIO)METHYL] 7 HYDROXY 6 METHOXY 8 [(2 METHYL 1H IMIDAZOL 1 YL)METHYL]QUINOLINE 3 CARBOXYLATE; ETHYL 2 [(4 METHOXYPHENYLSULFINYL)METHYL] 7 HYDROXY 6 METHOXY 8 [(2 METHYL 1H IMIDAZOL 1 YL)METHYL]QUINOLINE 3 CARBOXYLATE; ETHYL 2 [(4 METHOXYPHENYLSULFONYL)METHYL 7 HYDROXY 6 METHOXY 8 [(2 METHYL 1 YL)QUINOLINE 3 CARBOXYLATE; ETHYL 2 [(4 METHOXYPHENYLTHIO)METHYL] 7 HYDROXY 6 METHOXY 8 [(2 METHYL 1H IMIDAZOL 1 YL]METHYLQUINOLINE 3 CARBOXYLATE; ETHYL 7 HYDROXY 6 METHOXY 8 [(2 METHYL 1H IMIDAZOL 1 YL)METHYL] 2 [(PHENYLSULFINYL)METHYL]QUINOLINE 3 CARBOXYLATE; ETHYL 7 HYDROXY 6 METHOXY 8 [(2 METHYL 1H IMIDAZOL 1 YL)METHYL] 2 [(PHENYLSULFONYL)METHYL]QUINOLINE 3 CARBOXYLATE; ETHYL 7 HYDROXY 6 METHOXY 8 [(2 METHYL 1H IMIDAZOL 1 YL)METHYL] 2 [(PHENYLTHIO)METHYL]QUINOLINE 3 CARBOXYLATE; ETHYL 8 [(1H IMIDAZOL 1 YL) 2 [(3,4 DIFLUOROPHENYLSULFINYL)METHYL]7 HYDROXY 6 METHOXYGUINOLINE 3 CARBOXYLATE; ETHYL 8 [(1H IMIDAZOL 1 YL)METHYL 2 [(4 FLUOROPHENYLSULFINYL)METHYL] 7 HYDROXY 6 METHOXYQUINOLINE 3 CARBOXYLATE; ETHYL 8 [(1H IMIDAZOL 1 YL)METHYL 2 [(4 FLUOROPHENYLSULFONYL)METHYL] 7 HYDROXY 6 METHOXYQUINOLINE 3 CARBOXYLATE; ETHYL 8 [(1H IMIDAZOL 1 YL)METHYL] 2 [(3 METHYLPHENYLSULFINYL)METHYL] 7 HYDROXY 6 METHOXYQUINOLINE 3 CARBOXYLATE; ETHYL 8 [(1H IMIDAZOL 1 YL)METHYL] 2 [(3 METHYLPHENYLSULFONYL)METHYL] 7 HYDROXY 6 METHOXYQUINOLINE 3 CARBOXYLATE; ETHYL 8 [(1H IMIDAZOL 1 YL)METHYL] 2 [(3 METHYLPHENYLTHIO)METHYL 7 HYDROXY 6 METHOXYQUINOLINE 3 CARBOXYLATE; ETHYL 8 [(1H IMIDAZOL 1 YL)METHYL] 2 [(3,4 DIFLUOROPHENYLSULFONYL)METHYL] 7 HYDROXY 6 METHOXYQUINOLINE 3 CARBOXYLATE; ETHYL 8 [(1H IMIDAZOL 1 YL)METHYL] 2 [(4 FLUOROPHENYLTHIO)METHYL] 7 HYDROXY 6 METHOXYQUINOLINE 3 CARBOXYLATE; ETHYL 8 [(1H IMIDAZOL 1 YL)METHYL] 3 [(3,4 DIFLUOROPHENYLTHIO)METHYL] 7 HYDROXY 6 METHOXYQUINOLINE 3 CARBOXYLATE; ETHYL 8 [(1H IMIDAZOL 1 YL)METHYL] 7 HYDROXY 6 METHOXY 2 [(PHENYLSULFINYL)METHYL]QUINOLINE 3 CARBOXYLATE; ETHYL 8 [(1H IMIDAZOL 1 YL)METHYL] 7 HYDROXY 6 METHOXY 2 [(PHENYLSULFONYL)METHYL]QUINOLINE 3 CARBOXYLATE; ETHYL 8 [(1H IMIDAZOLE 1 YL)METHYL] 7 HYDROXY 6 METHOXY 2 [(PHENYLTHIO)METHYL]QUIOLINE 3 CARBOXYLATE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; UNCLASSIFIED DRUG; VIRUS DNA; ANTIVIRUS AGENT; CARBOXYLIC ACID; QUINOLINOL DERIVATIVE;

ANTIGEN EXPRESSION; ANTIVIRAL ACTIVITY; ARTICLE; CELL STRAIN HEPG2; CYTOTOXICITY; DRUG SYNTHESIS; HEPATITIS B; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; VIRUS REPLICATION; COMPARATIVE STUDY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HEPATITIS B VIRUS; SYNTHESIS; TUMOR CELL LINE;

ANTIVIRAL AGENTS; CARBOXYLIC ACIDS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; HYDROXYQUINOLINES; INHIBITORY CONCENTRATION 50; LAMIVUDINE; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION;

EID: 52449098355     PISSN: 03656233     EISSN: 15214184     Source Type: Journal    
DOI: 10.1002/ardp.200800035     Document Type: Article

References (15)

1. G. Dieter, World J. Gastroenterol. 2007, 13, 8-13.
2. M. Mailliard, J. Gollan, Annu. Rev. Med. 2006, 57, 155-166.
3. G. M. Dusheiko, I. Dinesen, Cytokine Handbook 2003, 2, 1233-1254.
4. K. P. Fischer, K. S. Gutfreund, D. L. Tyrrell, Drug Resist. Updat. 2001, 4, 118-128.
5. M. Danta, G. Dusheiko, Int. J. Clin. Pract. 2004, 58, 877-886.
6. K. A. Sims, A. W. Woodland, Pharmacotherapy 2006, 26, 1745-1757.
7. S. F. Chen, L. M. Papp, R. J. Ardecky, G. V. Rao, et al., Biochem. Pharmacol. 1990, 40, 709-714.
8. K. Mekouar, J. F. Mouscadet, D. Desmaële, F. Subra, et al., J. Med. Chem. 1998, 41, 2846-2857.
9. H. F. Chai, Y. F. Zhao, C. S. Zhao, P. Gong, Bioorg. Med. Chem. 2006, 14, 911-917.
10. C. S. Zhao, Y. F. Zhao, H. F. Chai, P. Gong, Bioorg. Med. Chem. 2006, 14, 2552-2558.
11. L. Pouysegu, A. V. Avellan, S. Quideau, J. Org. Chem. 2002, 67, 3425-3436.
12. S. C. Tsai, J. P. Klinman, Bioorg. Chem. 2003, 3, 172-190.
13. P. Friedländer, C. F. Gohring, Ber. Dtsch. Chem. Ges. 1883, 16, 1833-1835.
14. M. A. Sells, M. L. Chen, G. Acs, Proc. Natl. Acad. Sci. U.S.A. 1987, 84, 1005-1009.
15. B. E. Korba, J. L. Gerin, Antiviral Res. 1995, 28, 225-242.